Shiyu Zhou1, Zhenhua Zeng2, Hongxia Wei1, Tong Sha2, Shengli An3. 1. Department of Biostatistics, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research, Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering), Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou, 510515, People's Republic of China. 2. Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China. 3. Department of Biostatistics, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research, Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering), Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou, 510515, People's Republic of China. asl0418@126.com.
Abstract
BACKGROUND: Fluid therapy is a cornerstone in the treatment of sepsis. Recently, the guidelines have recommended the combined administration that using crystalloids plus albumin for septic patients, but the optimal timing for albumin combined is still unclear. The objective of this study was to investigate the association of timing of albumin combined with 28-day mortality in patients with sepsis. METHODS: We involved septic patients from the Medical Information Mart for Intensive Care (MIMIC)-IV database, and these patients were categorized into crystalloids group (crystalloids alone) and early combination group (crystalloids combined albumin at 0-24 h). The primary outcome was 28-day mortality. We used propensity score matching (PSM) to adjust confounding and restricted mean survival time (RMST) analysis was conducted to quantify the beneficial effect on survival due to the combination group. RESULTS: We categorized 6597 and 920 patients in the "crystalloids alone" and "early combination", respectively. After PSM, compared to the crystalloids group, the combination group was associated with the increased survival among 28-day (increased survival: 3.39 days, 95% CI 2.53-4.25; P < 0.001) after ICU admission. Patients who received albumin combination at the first 24-h was associated with prolonged LOS in ICU (10.72 days vs. 8.24 days; P < 0.001) but lower risk of 28-day mortality (12.5% vs 16.4%, P = 0.003) than those received crystalloids alone. CONCLUSION: In septic patients, receiving albumin combined within the first 24-h after crystalloids administration was associated with an increment of survival in 28 days.
BACKGROUND: Fluid therapy is a cornerstone in the treatment of sepsis. Recently, the guidelines have recommended the combined administration that using crystalloids plus albumin for septic patients, but the optimal timing for albumin combined is still unclear. The objective of this study was to investigate the association of timing of albumin combined with 28-day mortality in patients with sepsis. METHODS: We involved septic patients from the Medical Information Mart for Intensive Care (MIMIC)-IV database, and these patients were categorized into crystalloids group (crystalloids alone) and early combination group (crystalloids combined albumin at 0-24 h). The primary outcome was 28-day mortality. We used propensity score matching (PSM) to adjust confounding and restricted mean survival time (RMST) analysis was conducted to quantify the beneficial effect on survival due to the combination group. RESULTS: We categorized 6597 and 920 patients in the "crystalloids alone" and "early combination", respectively. After PSM, compared to the crystalloids group, the combination group was associated with the increased survival among 28-day (increased survival: 3.39 days, 95% CI 2.53-4.25; P < 0.001) after ICU admission. Patients who received albumin combination at the first 24-h was associated with prolonged LOS in ICU (10.72 days vs. 8.24 days; P < 0.001) but lower risk of 28-day mortality (12.5% vs 16.4%, P = 0.003) than those received crystalloids alone. CONCLUSION: In septic patients, receiving albumin combined within the first 24-h after crystalloids administration was associated with an increment of survival in 28 days.
Entities:
Keywords:
Albumins; Fluid therapy; Mortality; Restricted mean survival time; Sepsis
Authors: Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus Journal: JAMA Date: 2016-02-23 Impact factor: 56.272
Authors: Vincent Liu; Gabriel J Escobar; John D Greene; Jay Soule; Alan Whippy; Derek C Angus; Theodore J Iwashyna Journal: JAMA Date: 2014-07-02 Impact factor: 56.272
Authors: Sandra L Peake; Anthony Delaney; Michael Bailey; Rinaldo Bellomo; Peter A Cameron; D James Cooper; Alisa M Higgins; Anna Holdgate; Belinda D Howe; Steven A R Webb; Patricia Williams Journal: N Engl J Med Date: 2014-10-01 Impact factor: 91.245
Authors: Sameer S Kadri; Chanu Rhee; Jeffrey R Strich; Megan K Morales; Samuel Hohmann; Jonathan Menchaca; Anthony F Suffredini; Robert L Danner; Michael Klompas Journal: Chest Date: 2016-07-22 Impact factor: 9.410
Authors: Carolin Fleischmann; André Scherag; Neill K J Adhikari; Christiane S Hartog; Thomas Tsaganos; Peter Schlattmann; Derek C Angus; Konrad Reinhart Journal: Am J Respir Crit Care Med Date: 2016-02-01 Impact factor: 21.405